Scientific deep-dive
The Cochrane Verdict, and Who Funded the Evidence
Two WHO-funded Cochrane reviews confirm clinically relevant, sustained weight loss. Both also note the trials were paid for by the manufacturers: all of them, in tirzepatide's case.
Cochrane is the most conservative evidence organization in medicine, and it has now reviewed semaglutide and tirzepatide for obesity, funded by the World Health Organization. Both reviews conclude the drugs produce clinically relevant, sustained weight loss. Both also end on the same observation: the evidence base was paid for by the companies selling the drugs.[1][2]
What they concluded about weight
Start with the positive finding, because it is the main one. Semaglutide produces a clinically relevant weight loss at medium-term follow-up compared with placebo, likely sustained in the long term while taking the drug.[1] Tirzepatide likewise produces weight loss at medium-term follow-up, likely sustained longer term.[2]
That is Cochrane language, and Cochrane does not hand out “clinically relevant” casually. On the question these drugs are prescribed for, the answer is yes.
What they could not conclude
Everything else is where the certainty drains away, and the pattern is consistent across both reviews.
| Outcome | Finding | Certainty |
|---|---|---|
| Semaglutide — quality of life, major cardiovascular events, mortality | Effects likely limited or uncertain | Downgraded for risk of bias and imprecision |
| Tirzepatide — quality of life (SF-36 physical) | MD 2.70 (95% CI 0.00 to 5.40), 1 study, 1,032 participants | Low |
| Tirzepatide — mortality | RR 0.83 (95% CI 0.22 to 3.17), 1 study, 1,032 participants | Low |
The funding sentence
Both reviews say it, and Cochrane does not editorialize. For semaglutide: most studies were funded by the drug’s manufacturer, raising important concerns about conflicts of interest.[1] For tirzepatide, it is blunter — all of the included studies were funded by the drug manufacturer.[2]
Not most. All.
This is not an accusation that anyone falsified anything, and it should not be read as one. Industry funds most drug trials, because trials are expensive and regulators require them. But industry-funded trials systematically choose the questions, the comparators, the endpoints and the durations that suit the sponsor, and across medicine they report more favorable results than independent ones. Both reviews call for independent studies, particularly in underrepresented populations.[1][2]
What this changes for a reader
- The weight claim is solid. Two conservative reviews agree, and it is the claim these drugs are actually sold on.
- Claims beyond weight deserve more skepticism than they usually get — on quality of life and mortality the evidence is thin or graded low.
- “While taking the drug” is doing real work in the semaglutide conclusion. Our maintenance trial article covers what happens when people stop.
- Independent evidence is coming. The semaglutide review identified 46 ongoing studies that may strengthen future syntheses.
And when a seller cites “the evidence” at you, it is worth knowing that the evidence in question was, in the tirzepatide case, entirely funded by the company that makes it. That does not make it wrong. It makes it a reason to want more.
Frequently Asked Questions
References
Compare the sellers
Related research
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo, and by about the same amount whether or not the person had hypertension.
7 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. One generic remains.
10 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and no guidelines exist for this age group.
7 min read
GLP-1 Drugs and Rheumatoid Arthritis: One Study, and What It Cannot Tell You
A retrospective review of 215 patients found greater falls in disease activity and pain among those who took a GLP-1 than among those prescribed one who did not. Nearly a third stopped the drug within the year.
6 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section came off the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
SnagRx
Semaglutide at $99/month, 48% below the typical price
From $149/mo
Get started →Embody
Knowing which pharmacy fills the vial: it names RedRock Pharmacy
From $129/mo
Get started →YourEra
Semaglutide at $99/month, 63% below the typical price
From $99/mo
Get started →